

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

NCT07331272

Status	RECRUITING
Phase	Phase 1
Sponsor	Nanjing Legend Biotech Co.
Enrollment	38 participants

Key Eligibility Criteria

Inclusion (12)

- Subjects voluntary agreement to provide written informed consent.
- Aged 18 to 70 years, either sex.
- Adequate organ function meet screening criteria.
- Positive test for cluster of differentiation antigen 19 (CD19).
- SLE:
... and 7 more (see full listing online)

Exclusion (5)

- Active infections such as hepatitis and tuberculosis.
- Other autoimmune diseases.
- Serious underlying diseases such as tumor, uncontrolled diabetes.
- Female subjects who were pregnant, breastfeeding.
- Those with a history of major organ transplantation.

Locations (5 total)

The Third The People's Hospital of Bengbu, Bengbu, Anhui, China
Nanfang Hospital, Guangzhou, Guangdong, China
Xiangya Hospital of Central South University, Changsha, Hunan, China
... and 2 more locations